Provided by Tiger Fintech (Singapore) Pte. Ltd.

Rhythm Pharmaceuticals Inc.

100.71
+1.301.31%
Volume:466.70K
Turnover:47.12M
Market Cap:6.72B
PE:-32.43
High:101.98
Open:99.85
Low:99.57
Close:99.41
52wk High:116.00
52wk Low:45.91
Shares:66.74M
Float Shares:53.42M
Volume Ratio:0.74
T/O Rate:0.87%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1057
EPS(LYR):-4.3376
ROE:-85.79%
ROA:-26.74%
PB:45.16
PE(LYR):-23.22

Loading ...

Rhythm Pharmaceuticals Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Sep 26

Oppenheimer Sticks to Their Buy Rating for Rhythm Pharmaceuticals (RYTM)

TIPRANKS
·
Sep 25

Rhythm Pharmaceuticals price target raised to $122 from $109 at Morgan Stanley

TIPRANKS
·
Sep 25

Goldman Sachs Remains a Buy on Rhythm Pharmaceuticals (RYTM)

TIPRANKS
·
Sep 24

Rhythm Pharmaceuticals Inc. Unveils Presentation on Advancing MC4R Agonists and IMCIVREE® Sales Growth

Reuters
·
Sep 10

Joseph Shulman, Chief Technical Officer, Reports Disposal of Common Shares in Rhythm Pharmaceuticals Inc

Reuters
·
Aug 26

Rhythm Pharmaceuticals Announces FDA Priority Review for Setmelanotide in Acquired Hypothalamic Obesity, PDUFA Date Set for December 20, 2025

Reuters
·
Aug 21

Rhythm Pharmaceuticals Inc - Study Met Primary Endpoint With -19.8% Placebo-Adj Bmi Reduction

THOMSON REUTERS
·
Aug 21

Rhythm Pharmaceuticals Inc - FDA Grants Priority Review With Pdufa Date December 20, 2025

THOMSON REUTERS
·
Aug 21

Hunter C. Smith, CFO, Reports Disposal of Common Shares of Rhythm Pharmaceuticals Inc

Reuters
·
Aug 15

LIVE MARKETS-Prader-Willi drug sparks Wall Street interest in multi-billion dollar market, Leerink says

Reuters
·
Aug 14

Chief Technical Officer Joseph Shulman Reports Disposal of Common Shares in Rhythm Pharmaceuticals Inc

Reuters
·
Aug 14

Rhythm Pharmaceuticals, Inc. : H.c. Wainwright Raises Target Price to $100 From $80

THOMSON REUTERS
·
Aug 07

Rhythm Pharmaceuticals Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Aug 07

Earnings Flash (RYTM) Rhythm Pharmaceuticals Posts Q2 Net Loss $0.75, vs. FactSet Est of $0.75 Loss

MT Newswires Live
·
Aug 05

Rhythm Pharmaceuticals Q2 EPS $(0.75) Misses $(0.64) Estimate, Sales $48.50M Beat $43.72M Estimate

Benzinga
·
Aug 05

BRIEF-Rhythm Pharmaceuticals Q2 Net Income USD -46.632 Million Vs. IBES Estimate USD -41.3 Million

Reuters
·
Aug 05

Rhythm Pharmaceuticals Q2 Operating Income USD -45.296 Million

THOMSON REUTERS
·
Aug 05

Rhythm Pharmaceuticals Inc - Q2 EPS $-0.75

THOMSON REUTERS
·
Aug 05

Rhythm Pharmaceuticals - US and EU Regulatory Submissions for Setmelanotide in Acquired Hypothalamic Obesity on Track to Be Completed in Q3

THOMSON REUTERS
·
Aug 05